Agalsidase alfa
Therapeutic Indications
Agalsidase alfa is indicated for:
Fabry Disease
Irrespective of gender only Children (1 year - 12 years old) , Adolescents (12 years - 18 years old)
Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 0.2 mg/kg every other week
Fabry Disease
Irrespective of gender only Adults (18 - 65 years old)
Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 0.2 mg/kg every other week
Contraindications
Active ingredient Agalsidase alfa is contraindicated in the following cases:
Amiodarone
No gender/age discrimination
Agalsidase alfa should not be co-administered with amiodarone since this substance has the potential to inhibit intra-cellular α-galactosidase activity.
Chloroquine
No gender/age discrimination
Agalsidase alfa should not be co-administered with chloroquine since this substance has the potential to inhibit intra-cellular α-galactosidase activity.
Gentamicin
No gender/age discrimination
Agalsidase alfa should not be co-administered with gentamicin since this substance has the potential to inhibit intra-cellular α-galactosidase activity.